1 of 3
FEATURED COMPANIES
- Allergan Plc
- Basilea Pharmaceutica
- Cubist Pharmaceutical
- Durata Therapeutics
- Melinta
- Motif Bio
- MORE
‘Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Acute Bacterial Skin and Skin-Structure Infection in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Acute Bacterial Skin and Skin-Structure Infection from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market
Geography Covered
Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) - Disease Understanding and Treatment Algorithm
According to the U.S. Food and Drug Administration (FDA), ABSSSI is defined as a bacterial infection of skin with a lesion size area of =75 cm2 (lesion size measured by the area of redness, oedema or induration). ABSSSIs consist of the most frequently diagnosed skin infections worldwide. The symptoms observed in ABSSSI are extensive cellulitis, wound infection, major cutaneous abscesses, and burn infections. There are several pathogens that lead to ABSSSIs, such as Methicillin sensitive Staphylococcus aureus (MSSA), Methicillin resistant Staphylococcus aureus (MRSA), Beta-hemolytic Streptococcus, Escherichia coli, Enterococcus faecalis, Pseudomonas aeruginosa, and others
The Acute Bacterial Skin and Skin-Structure Infection market report gives the thorough understanding of the Acute Bacterial Skin and Skin-Structure Infection by including details such as disease definition, causes, symptoms, risk factors, pathophysiology and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Acute Bacterial Skin and Skin-Structure Infection in the US, Europe, and Japan
Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Epidemiology
The Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident Population of Acute Bacterial Skin and Skin-Structure Infection, Gender-specific Incidence Cases of Acute Bacterial Skin and Skin-Structure Infection, Subtype-specific Incidence Cases of Acute Bacterial Skin and Skin-Structure Infection, Incidence cases of ABSSSI by Clinical Manifestations, Diagnosed and Treatable Cases of Acute Bacterial Skin and Skin-Structure Infection) scenario of Acute Bacterial Skin and Skin-Structure Infection in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028
As per Kaye et al, a total of 1.8% of hospital admissions for the years 2005 through 2011 were for adult patients with a SSSI primary diagnosis. According to this research, the total number of incident population of Acute Bacterial Skin and Skin-Structure Infection will change from the study period 2017-2028
Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Drug Chapters
This segment of the Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases
According to The Infectious Diseases Society of America (IDSA) guidelines for the treatment of skin and soft tissue infections in 2014, the treatment of typical cases of cellulitis (major subtype of ABSSSI) includes an oral antibiotic with activity against streptococci. Major treatment options for mild cases of non-purulent infections include penicillin, amoxicillin, amoxicillin-clavulanate, dicloxacillin, cephalexin, and clindamycin. Oral and intravenous options for the treatment of ABSSSIs with activity against MRSA include several long-standing therapies, such as sulfamethoxazole-trimethoprim, clindamycin, minocycline, doxycycline, vancomycin, daptomycin, linezolid, ceftaroline, and telavancin. Antibiotics with activity against MRSA are considered when the infection is associated with penetrating trauma, such as IV drug use
To meet the increasing demand for the treatment of Acute Bacterial Skin and Skin-Structure Infection, companies have shifted their focus towards the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the Incident population of Acute Bacterial Skin and Skin-Structure Infection & awareness of the disease. The overall dynamics of Acute Bacterial Skin and Skin-Structure Infection market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as Merck Sharp & Dohme Corp., Motif Bio, MicuRx, Durata Therapeutics, Wockhardt and some others, will significantly increase the market during the forecast period (2019-2028).
Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Market Outlook
The Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight
According to this research, the market of Acute Bacterial Skin and Skin-Structure Infection in 7MM is expected to change from 2019-2028
Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions
Expected launch of therapies for Acute Bacterial Skin and Skin-Structure Infection such as MK-1986 (Merck Sharp & Dohme Corp), Iclaprim (Motif Bio), MRX-I (MicuRx) and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Acute Bacterial Skin and Skin-Structure Infection market
Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Report Insights
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Acute Bacterial Skin and Skin-Structure Infection from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) - Disease Understanding and Treatment Algorithm
According to the U.S. Food and Drug Administration (FDA), ABSSSI is defined as a bacterial infection of skin with a lesion size area of =75 cm2 (lesion size measured by the area of redness, oedema or induration). ABSSSIs consist of the most frequently diagnosed skin infections worldwide. The symptoms observed in ABSSSI are extensive cellulitis, wound infection, major cutaneous abscesses, and burn infections. There are several pathogens that lead to ABSSSIs, such as Methicillin sensitive Staphylococcus aureus (MSSA), Methicillin resistant Staphylococcus aureus (MRSA), Beta-hemolytic Streptococcus, Escherichia coli, Enterococcus faecalis, Pseudomonas aeruginosa, and others
The Acute Bacterial Skin and Skin-Structure Infection market report gives the thorough understanding of the Acute Bacterial Skin and Skin-Structure Infection by including details such as disease definition, causes, symptoms, risk factors, pathophysiology and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Acute Bacterial Skin and Skin-Structure Infection in the US, Europe, and Japan
Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Epidemiology
The Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident Population of Acute Bacterial Skin and Skin-Structure Infection, Gender-specific Incidence Cases of Acute Bacterial Skin and Skin-Structure Infection, Subtype-specific Incidence Cases of Acute Bacterial Skin and Skin-Structure Infection, Incidence cases of ABSSSI by Clinical Manifestations, Diagnosed and Treatable Cases of Acute Bacterial Skin and Skin-Structure Infection) scenario of Acute Bacterial Skin and Skin-Structure Infection in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028
As per Kaye et al, a total of 1.8% of hospital admissions for the years 2005 through 2011 were for adult patients with a SSSI primary diagnosis. According to this research, the total number of incident population of Acute Bacterial Skin and Skin-Structure Infection will change from the study period 2017-2028
Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Drug Chapters
This segment of the Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases
According to The Infectious Diseases Society of America (IDSA) guidelines for the treatment of skin and soft tissue infections in 2014, the treatment of typical cases of cellulitis (major subtype of ABSSSI) includes an oral antibiotic with activity against streptococci. Major treatment options for mild cases of non-purulent infections include penicillin, amoxicillin, amoxicillin-clavulanate, dicloxacillin, cephalexin, and clindamycin. Oral and intravenous options for the treatment of ABSSSIs with activity against MRSA include several long-standing therapies, such as sulfamethoxazole-trimethoprim, clindamycin, minocycline, doxycycline, vancomycin, daptomycin, linezolid, ceftaroline, and telavancin. Antibiotics with activity against MRSA are considered when the infection is associated with penetrating trauma, such as IV drug use
To meet the increasing demand for the treatment of Acute Bacterial Skin and Skin-Structure Infection, companies have shifted their focus towards the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the Incident population of Acute Bacterial Skin and Skin-Structure Infection & awareness of the disease. The overall dynamics of Acute Bacterial Skin and Skin-Structure Infection market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as Merck Sharp & Dohme Corp., Motif Bio, MicuRx, Durata Therapeutics, Wockhardt and some others, will significantly increase the market during the forecast period (2019-2028).
Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Market Outlook
The Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight
According to this research, the market of Acute Bacterial Skin and Skin-Structure Infection in 7MM is expected to change from 2019-2028
Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions
Expected launch of therapies for Acute Bacterial Skin and Skin-Structure Infection such as MK-1986 (Merck Sharp & Dohme Corp), Iclaprim (Motif Bio), MRX-I (MicuRx) and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Acute Bacterial Skin and Skin-Structure Infection market
Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Report Insights
- Patient Population
- Therapeutic Approaches
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
- Current Treatment Practices
- Unmet Needs
- Market Attractiveness
- Market Drivers and Barriers
- This report will help to develop Business Strategies by understanding the trends shaping and driving Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) market
- Organize sales and marketing efforts by identifying the best opportunities for Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) market
- To understand the future market competition in the Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) market
Note: Product cover images may vary from those shown
2 of 3
FEATURED COMPANIES
- Allergan Plc
- Basilea Pharmaceutica
- Cubist Pharmaceutical
- Durata Therapeutics
- Melinta
- Motif Bio
- MORE
1. Report Introduction
2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) : Market Overview at a Glance
2.1. 7 Major Market Size (%) of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) in 2017
2.2. 7 Major Market Size (%) of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) in 2028
3. Disease Background and Overview: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
3.1. Introduction
3.2. Causes
3.3. Pathophysiology
3.4. Symptoms
3.5. Risk Factor
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. 7MM Total Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
4.2. 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
4.3. 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
4.4. 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident cases by Clinical Manifestations (2017-2028)
4.5. 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) : Country- Wise Epidemiology
5.1. United States
5.1.1. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
5.1.2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
5.1.3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
5.1.4. ABSSSI Incident cases by Clinical Manifestations (2017-2028)
5.1.5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
5.2. EU-5
5.2.1. Assumptions and Rationale
5.2.2. Germany
5.2.2.1. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
5.2.2.2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
5.2.2.3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
5.2.2.4. ABSSSI Incident cases by Clinical Manifestations (2017-2028)
5.2.2.5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
5.2.3. France
5.2.3.1. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
5.2.3.2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
5.2.3.3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
5.2.3.4. ABSSSI Incident cases by Clinical Manifestations (2017-2028)
5.2.3.5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
5.2.4. Italy
5.2.4.1. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
5.2.4.2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
5.2.4.3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
5.2.4.4. ABSSSI Incident cases by Clinical Manifestations (2017-2028)
5.2.4.5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
5.2.5. Spain
5.2.5.1. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
5.2.5.2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
5.2.5.3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
5.2.5.4. ABSSSI Incident cases by Clinical Manifestations (2017-2028)
5.2.5.5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
5.2.6. United Kingdom
5.2.6.1. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
5.2.6.2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
5.2.6.3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
5.2.6.4. ABSSSI Incident cases by Clinical Manifestations (2017-2028)
5.2.6.5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
5.3. Japan
5.3.1. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
5.3.2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
5.3.3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
5.3.4. ABSSSI Incident cases by Clinical Manifestations (2017-2028)
5.3.5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
6. Treatments & Medical Practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Marketed drugs
7.1. List of Marketed Drugs
7.2. Dalvance - Durata Therapeutics
7.2.1. Mechanism of action
7.2.2. Regulatory Milestones
7.2.3. Advantage and disadvantage
7.2.4. Safety and efficacy
7.2.5. Side effects
7.2.6. Product profile
7.3. Baxdela - Melinta Therapeutics
7.3.1. Mechanism of action
7.3.2. Regulatory Milestones
7.3.3. Advantage and disadvantage
7.3.4. Safety and efficacy
7.3.5. Side effects
7.3.6. Product profile
8. Emerging Therapies
8.1. Key Cross Competition
8.2. MK-1986: Merck Sharp & Dohme Corp.
8.2.1. Regulatory Milestones
8.2.2. Clinical Development
8.2.3. Product Profile
8.2.4. Clinical Pipeline Activity
8.2.4.1. Ongoing Trials Information
8.2.4.2. Clinical Trial by Phase
8.3. MRX-I: MicuRx
8.3.1. Regulatory Milestones
8.3.2. Clinical Development
8.3.3. Product Profile
8.3.4. Clinical Pipeline Activity
8.3.4.1. Ongoing Trials Information
8.3.4.2. Clinical Trials by Phase
8.4. Iclaprim: MotifBio
8.4.1. Regulatory Milestones
8.4.2. Clinical Development
8.4.3. Product Profile
8.4.4. Clinical Pipeline Activity
8.4.4.1. Ongoing Trials Information
8.4.4.2. Clinical Trial by Phase
9. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) : Market Size
9.1. Key Findings
9.2. Total 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Market Analysis
9.2.1. Overview of Total Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Market
9.2.2. Market size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Market by 7MM (2017-2028)
10. 7MM: Country-Wise Market Analysis
10.1. United States Market Size
10.1.1. Total Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
10.1.2. Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) by Therapies
10.2. Germany Market Size
10.2.1. Total Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
10.2.2. Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) by Therapies
10.3. France Market Size
10.3.1. Total Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
10.3.2. Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) by Therapies
10.4. United Kingdom Market Size
10.4.1. Total Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
10.4.2. Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) by Therapies
10.5. Spain Market Size
10.5.1. Total Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
10.5.2. Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) by Therapies
10.6. Italy Market Size
10.6.1. Total Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
10.6.2. Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) by Therapies
10.7. Japan Market Size
10.7.1. Total Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
10.7.2. Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) by Therapies
11. Market Drivers
12. Market Barriers
13. Report Methodology
13.1. Sources Used
14. Publisher Capabilities
15. Disclaimer
16. About the Publisher
List of Tables
Table 1: 7MM Total Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
Table 2:7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
Table 3:7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
Table 4: 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident cases by Clinical Manifestations (2017-2028)
Table 5: 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
Table 6: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in the United States (2017-2028)
Table 7: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in the United States (2017-2028)
Table 8: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in the United States (2017-2028)
Table 9: ABSSSI Incident cases by Clinical Manifestations in the United States (2017-2028)
Table 10: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in the United States (2017-2028)
Table 11: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Germany (2017-2028)
Table 12: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Germany (2017-2028)
Table 13: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Germany (2017-2028)
Table 14: ABSSSI Incident cases by Clinical Manifestations in Germany (2017-2028)
Table 15: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Germany (2017-2028)
Table 16: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in France (2017-2028)
Table 17: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in France (2017-2028)
Table 18: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in France (2017-2028)
Table 19: ABSSSI Incident cases by Clinical Manifestations in France (2017-2028)
Table 20: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in France (2017-2028)
Table 21: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Italy (2017-2028)
Table 22: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Italy (2017-2028)
Table 23: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Italy (2017-2028)
Table 24: ABSSSI Incident cases by Clinical Manifestations in Italy (2017-2028)
Table 25: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Italy (2017-2028)
Table 26: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Spain (2017-2028)
Table 27: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Spain (2017-2028)
Table 28: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Spain (2017-2028)
Table 29: ABSSSI Incident cases by Clinical Manifestations in Spain (2017-2028)
Table 30: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Spain (2017-2028)
Table 31: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in the United Kingdom (2017-2028)
Table 32: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases the United Kingdom (2017-2028)
Table 33: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases the United Kingdom (2017-2028)
Table 34: ABSSSI Incident cases by Clinical Manifestations the United Kingdom (2017-2028)
Table 35: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases the United Kingdom (2017-2028)
Table 36: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Japan (2017-2028)
Table 37: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Japan (2017-2028)
Table 38: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Japan (2017-2028)
Table 39: ABSSSI Incident cases by Clinical Manifestations in Japan (2017-2028)
Table 40: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Japan (2017-2028)
Table 41: MK-1986, Clinical Trials by Recruitment status, 2019
Table 42: MK-1986, Clinical Trials by Zone, 2019
Table 43: MRX-I, Clinical Trials by Recruitment status, 2019
Table 44: MRX-I, Clinical Trials by Zone, 2019
Table 45: Total 7 Major Market Size in USD, Million (2017-2028)
Table 46: Region wise Market Size in USD, Million (2017-2028)
Table 47: 7MM-Market Size by Therapy in USD, Million (2017-2028)
Table 48: United States Market Size in USD, Million (2017-2028)
Table 49: United States Market Size by Therapy in USD, Million (2017-2028)
Table 50: Germany Market Size in USD, Million (2017-2028)
Table 51: Germany Market Size by Therapy in USD, Million (2017-2028)
Table 52: France Market Size in USD, Million (2017-2028)
Table 53: France Market Size by Therapy in USD, Million (2017-2028)
Table 54: Italy Market Size in USD, Million (2017-2028)
Table 55: Italy Market Size by Therapy in USD, Million (2017-2028)
Table 56: Spain Market Size in USD, Million (2017-2028)
Table 57: Spain Market Size by Therapy in USD, Million (2017-2028)
Table 58: United Kingdom Market Size in USD, Million (2017-2028)
Table 59: United Kingdom Market Size by Therapy in USD, Million (2017-2028)
Table 60: Japan Market Size in USD, Million (2017-2028)
Table 61: Japan Market Size by Therapy in USD, Million (2017-2028)
List of Figures
Figure 1: 7MM Total Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
Figure 2: 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
Figure 3: 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
Figure 4: 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident cases by Clinical Manifestations (2017-2028)
Figure 5: 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
Figure 6: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in the United States (2017-2028)
Figure 7: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in the United States (2017-2028)
Figure 8: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in the United States (2017-2028)
Figure 9: ABSSSI Incident cases by Clinical Manifestations in the United States (2017-2028)
Figure 10: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in the United States (2017-2028)
Figure 11: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Germany (2017-2028)
Figure 12: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Germany (2017-2028)
Figure 13: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Germany (2017-2028)
Figure 14: ABSSSI Incident cases by Clinical Manifestations in Germany (2017-2028)
Figure 15: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Germany (2017-2028)
Figure 16: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in France (2017-2028)
Figure 17: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in France (2017-2028)
Figure 18: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in France (2017-2028)
Figure 19: ABSSSI Incident cases by Clinical Manifestations in France (2017-2028)
Figure 20: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in France (2017-2028)
Figure 21: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Italy (2017-2028)
Figure 22: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Italy (2017-2028)
Figure 23: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Italy (2017-2028)
Figure 24: ABSSSI Incident cases by Clinical Manifestations in Italy (2017-2028)
Figure 25: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Italy (2017-2028)
Figure 26: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Spain (2017-2028)
Figure 27: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Spain (2017-2028)
Figure 28: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Spain (2017-2028)
Figure 29: ABSSSI Incident cases by Clinical Manifestations in Spain (2017-2028)
Figure 30: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Spain (2017-2028)
Figure 31: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in the United Kingdom (2017-2028)
Figure 32: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases the United Kingdom (2017-2028)
Figure 33: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases the United Kingdom (2017-2028)
Figure 34: ABSSSI Incident cases by Clinical Manifestations the United Kingdom (2017-2028)
Figure 35: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases the United Kingdom (2017-2028)
Figure 36: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Japan (2017-2028)
Figure 37: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Japan (2017-2028)
Figure 38: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Japan (2017-2028)
Figure 39: ABSSSI Incident cases by Clinical Manifestations in Japan (2017-2028)
Figure 40: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Japan (2017-2028)
Figure 41: MK-1986, Clinical Trials by Recruitment status, 2019
Figure 42: MK-1986, Clinical Trials by Zone, 2019
Figure 43: MRX-I, Clinical Trials by Recruitment status, 2019
Figure 44: MRX-I, Clinical Trials by Zone, 2019
Figure 45: Total 7 Major Market Size in USD, Million (2017-2028)
Figure 46: Region wise Market Size in USD, Million (2017-2028)
Figure 47: 7MM-Market Size by Therapy in USD, Million (2017-2028)
Figure 48: United States Market Size in USD, Million (2017-2028)
Figure 49: United States Market Size by Therapy in USD, Million (2017-2028)
Figure 50: Germany Market Size in USD, Million (2017-2028)
Figure 51: Germany Market Size by Therapy in USD, Million (2017-2028)
Figure 52: France Market Size in USD, Million (2017-2028)
Figure 53: France Market Size by Therapy in USD, Million (2017-2028)
Figure 54: Italy Market Size in USD, Million (2017-2028)
Figure 55: Italy Market Size by Therapy in USD, Million (2017-2028)
Figure 56: Spain Market Size in USD, Million (2017-2028)
Figure 57: Spain Market Size by Therapy in USD, Million (2017-2028)
Figure 58: United Kingdom Market Size in USD, Million (2017-2028)
Figure 59: United Kingdom Market Size by Therapy in USD, Million (2017-2028)
Figure 60: Japan Market Size in USD, Million (2017-2028)
Figure 61: Japan Market Size by Therapy in USD, Million (2017-2028)
2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) : Market Overview at a Glance
2.1. 7 Major Market Size (%) of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) in 2017
2.2. 7 Major Market Size (%) of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) in 2028
3. Disease Background and Overview: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
3.1. Introduction
3.2. Causes
3.3. Pathophysiology
3.4. Symptoms
3.5. Risk Factor
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. 7MM Total Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
4.2. 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
4.3. 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
4.4. 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident cases by Clinical Manifestations (2017-2028)
4.5. 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) : Country- Wise Epidemiology
5.1. United States
5.1.1. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
5.1.2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
5.1.3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
5.1.4. ABSSSI Incident cases by Clinical Manifestations (2017-2028)
5.1.5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
5.2. EU-5
5.2.1. Assumptions and Rationale
5.2.2. Germany
5.2.2.1. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
5.2.2.2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
5.2.2.3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
5.2.2.4. ABSSSI Incident cases by Clinical Manifestations (2017-2028)
5.2.2.5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
5.2.3. France
5.2.3.1. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
5.2.3.2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
5.2.3.3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
5.2.3.4. ABSSSI Incident cases by Clinical Manifestations (2017-2028)
5.2.3.5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
5.2.4. Italy
5.2.4.1. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
5.2.4.2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
5.2.4.3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
5.2.4.4. ABSSSI Incident cases by Clinical Manifestations (2017-2028)
5.2.4.5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
5.2.5. Spain
5.2.5.1. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
5.2.5.2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
5.2.5.3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
5.2.5.4. ABSSSI Incident cases by Clinical Manifestations (2017-2028)
5.2.5.5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
5.2.6. United Kingdom
5.2.6.1. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
5.2.6.2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
5.2.6.3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
5.2.6.4. ABSSSI Incident cases by Clinical Manifestations (2017-2028)
5.2.6.5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
5.3. Japan
5.3.1. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
5.3.2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
5.3.3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
5.3.4. ABSSSI Incident cases by Clinical Manifestations (2017-2028)
5.3.5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
6. Treatments & Medical Practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Marketed drugs
7.1. List of Marketed Drugs
7.2. Dalvance - Durata Therapeutics
7.2.1. Mechanism of action
7.2.2. Regulatory Milestones
7.2.3. Advantage and disadvantage
7.2.4. Safety and efficacy
7.2.5. Side effects
7.2.6. Product profile
7.3. Baxdela - Melinta Therapeutics
7.3.1. Mechanism of action
7.3.2. Regulatory Milestones
7.3.3. Advantage and disadvantage
7.3.4. Safety and efficacy
7.3.5. Side effects
7.3.6. Product profile
8. Emerging Therapies
8.1. Key Cross Competition
8.2. MK-1986: Merck Sharp & Dohme Corp.
8.2.1. Regulatory Milestones
8.2.2. Clinical Development
8.2.3. Product Profile
8.2.4. Clinical Pipeline Activity
8.2.4.1. Ongoing Trials Information
8.2.4.2. Clinical Trial by Phase
8.3. MRX-I: MicuRx
8.3.1. Regulatory Milestones
8.3.2. Clinical Development
8.3.3. Product Profile
8.3.4. Clinical Pipeline Activity
8.3.4.1. Ongoing Trials Information
8.3.4.2. Clinical Trials by Phase
8.4. Iclaprim: MotifBio
8.4.1. Regulatory Milestones
8.4.2. Clinical Development
8.4.3. Product Profile
8.4.4. Clinical Pipeline Activity
8.4.4.1. Ongoing Trials Information
8.4.4.2. Clinical Trial by Phase
9. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) : Market Size
9.1. Key Findings
9.2. Total 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Market Analysis
9.2.1. Overview of Total Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Market
9.2.2. Market size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Market by 7MM (2017-2028)
10. 7MM: Country-Wise Market Analysis
10.1. United States Market Size
10.1.1. Total Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
10.1.2. Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) by Therapies
10.2. Germany Market Size
10.2.1. Total Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
10.2.2. Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) by Therapies
10.3. France Market Size
10.3.1. Total Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
10.3.2. Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) by Therapies
10.4. United Kingdom Market Size
10.4.1. Total Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
10.4.2. Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) by Therapies
10.5. Spain Market Size
10.5.1. Total Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
10.5.2. Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) by Therapies
10.6. Italy Market Size
10.6.1. Total Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
10.6.2. Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) by Therapies
10.7. Japan Market Size
10.7.1. Total Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
10.7.2. Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) by Therapies
11. Market Drivers
12. Market Barriers
13. Report Methodology
13.1. Sources Used
14. Publisher Capabilities
15. Disclaimer
16. About the Publisher
List of Tables
Table 1: 7MM Total Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
Table 2:7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
Table 3:7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
Table 4: 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident cases by Clinical Manifestations (2017-2028)
Table 5: 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
Table 6: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in the United States (2017-2028)
Table 7: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in the United States (2017-2028)
Table 8: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in the United States (2017-2028)
Table 9: ABSSSI Incident cases by Clinical Manifestations in the United States (2017-2028)
Table 10: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in the United States (2017-2028)
Table 11: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Germany (2017-2028)
Table 12: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Germany (2017-2028)
Table 13: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Germany (2017-2028)
Table 14: ABSSSI Incident cases by Clinical Manifestations in Germany (2017-2028)
Table 15: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Germany (2017-2028)
Table 16: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in France (2017-2028)
Table 17: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in France (2017-2028)
Table 18: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in France (2017-2028)
Table 19: ABSSSI Incident cases by Clinical Manifestations in France (2017-2028)
Table 20: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in France (2017-2028)
Table 21: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Italy (2017-2028)
Table 22: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Italy (2017-2028)
Table 23: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Italy (2017-2028)
Table 24: ABSSSI Incident cases by Clinical Manifestations in Italy (2017-2028)
Table 25: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Italy (2017-2028)
Table 26: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Spain (2017-2028)
Table 27: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Spain (2017-2028)
Table 28: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Spain (2017-2028)
Table 29: ABSSSI Incident cases by Clinical Manifestations in Spain (2017-2028)
Table 30: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Spain (2017-2028)
Table 31: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in the United Kingdom (2017-2028)
Table 32: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases the United Kingdom (2017-2028)
Table 33: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases the United Kingdom (2017-2028)
Table 34: ABSSSI Incident cases by Clinical Manifestations the United Kingdom (2017-2028)
Table 35: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases the United Kingdom (2017-2028)
Table 36: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Japan (2017-2028)
Table 37: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Japan (2017-2028)
Table 38: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Japan (2017-2028)
Table 39: ABSSSI Incident cases by Clinical Manifestations in Japan (2017-2028)
Table 40: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Japan (2017-2028)
Table 41: MK-1986, Clinical Trials by Recruitment status, 2019
Table 42: MK-1986, Clinical Trials by Zone, 2019
Table 43: MRX-I, Clinical Trials by Recruitment status, 2019
Table 44: MRX-I, Clinical Trials by Zone, 2019
Table 45: Total 7 Major Market Size in USD, Million (2017-2028)
Table 46: Region wise Market Size in USD, Million (2017-2028)
Table 47: 7MM-Market Size by Therapy in USD, Million (2017-2028)
Table 48: United States Market Size in USD, Million (2017-2028)
Table 49: United States Market Size by Therapy in USD, Million (2017-2028)
Table 50: Germany Market Size in USD, Million (2017-2028)
Table 51: Germany Market Size by Therapy in USD, Million (2017-2028)
Table 52: France Market Size in USD, Million (2017-2028)
Table 53: France Market Size by Therapy in USD, Million (2017-2028)
Table 54: Italy Market Size in USD, Million (2017-2028)
Table 55: Italy Market Size by Therapy in USD, Million (2017-2028)
Table 56: Spain Market Size in USD, Million (2017-2028)
Table 57: Spain Market Size by Therapy in USD, Million (2017-2028)
Table 58: United Kingdom Market Size in USD, Million (2017-2028)
Table 59: United Kingdom Market Size by Therapy in USD, Million (2017-2028)
Table 60: Japan Market Size in USD, Million (2017-2028)
Table 61: Japan Market Size by Therapy in USD, Million (2017-2028)
List of Figures
Figure 1: 7MM Total Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
Figure 2: 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
Figure 3: 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
Figure 4: 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident cases by Clinical Manifestations (2017-2028)
Figure 5: 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
Figure 6: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in the United States (2017-2028)
Figure 7: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in the United States (2017-2028)
Figure 8: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in the United States (2017-2028)
Figure 9: ABSSSI Incident cases by Clinical Manifestations in the United States (2017-2028)
Figure 10: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in the United States (2017-2028)
Figure 11: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Germany (2017-2028)
Figure 12: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Germany (2017-2028)
Figure 13: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Germany (2017-2028)
Figure 14: ABSSSI Incident cases by Clinical Manifestations in Germany (2017-2028)
Figure 15: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Germany (2017-2028)
Figure 16: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in France (2017-2028)
Figure 17: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in France (2017-2028)
Figure 18: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in France (2017-2028)
Figure 19: ABSSSI Incident cases by Clinical Manifestations in France (2017-2028)
Figure 20: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in France (2017-2028)
Figure 21: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Italy (2017-2028)
Figure 22: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Italy (2017-2028)
Figure 23: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Italy (2017-2028)
Figure 24: ABSSSI Incident cases by Clinical Manifestations in Italy (2017-2028)
Figure 25: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Italy (2017-2028)
Figure 26: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Spain (2017-2028)
Figure 27: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Spain (2017-2028)
Figure 28: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Spain (2017-2028)
Figure 29: ABSSSI Incident cases by Clinical Manifestations in Spain (2017-2028)
Figure 30: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Spain (2017-2028)
Figure 31: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in the United Kingdom (2017-2028)
Figure 32: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases the United Kingdom (2017-2028)
Figure 33: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases the United Kingdom (2017-2028)
Figure 34: ABSSSI Incident cases by Clinical Manifestations the United Kingdom (2017-2028)
Figure 35: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases the United Kingdom (2017-2028)
Figure 36: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Japan (2017-2028)
Figure 37: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Japan (2017-2028)
Figure 38: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Japan (2017-2028)
Figure 39: ABSSSI Incident cases by Clinical Manifestations in Japan (2017-2028)
Figure 40: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Japan (2017-2028)
Figure 41: MK-1986, Clinical Trials by Recruitment status, 2019
Figure 42: MK-1986, Clinical Trials by Zone, 2019
Figure 43: MRX-I, Clinical Trials by Recruitment status, 2019
Figure 44: MRX-I, Clinical Trials by Zone, 2019
Figure 45: Total 7 Major Market Size in USD, Million (2017-2028)
Figure 46: Region wise Market Size in USD, Million (2017-2028)
Figure 47: 7MM-Market Size by Therapy in USD, Million (2017-2028)
Figure 48: United States Market Size in USD, Million (2017-2028)
Figure 49: United States Market Size by Therapy in USD, Million (2017-2028)
Figure 50: Germany Market Size in USD, Million (2017-2028)
Figure 51: Germany Market Size by Therapy in USD, Million (2017-2028)
Figure 52: France Market Size in USD, Million (2017-2028)
Figure 53: France Market Size by Therapy in USD, Million (2017-2028)
Figure 54: Italy Market Size in USD, Million (2017-2028)
Figure 55: Italy Market Size by Therapy in USD, Million (2017-2028)
Figure 56: Spain Market Size in USD, Million (2017-2028)
Figure 57: Spain Market Size by Therapy in USD, Million (2017-2028)
Figure 58: United Kingdom Market Size in USD, Million (2017-2028)
Figure 59: United Kingdom Market Size by Therapy in USD, Million (2017-2028)
Figure 60: Japan Market Size in USD, Million (2017-2028)
Figure 61: Japan Market Size by Therapy in USD, Million (2017-2028)
Note: Product cover images may vary from those shown
3 of 3
LOADING...
4 of 3
- Cubist Pharmaceutical
- Paratek Pharmaceutical
- Melinta
- Durata Therapeutics
- The Medicine Company
- Weyth Pharmaceutical
- Cubist Pharmaceutical
- Pfizer
- Allergan Plc
- Basilea Pharmaceutica
- Arrevus
- Motif Bio
- GlaxoSmithKline
- Debiopharm Group
- MicuRx Pharmaceuticals
- Innovation Pharmaceuticals
Note: Product cover images may vary from those shown
